Close
Seminar
series event

Discovery of Bedaquiline - New drug for drug-resistant Tuberculosis

The discovery of bedaquiline as a novel drug for treatment of multi-drug resistant tuberculosis has been now approved by more than 30 countries in the world including US,  Europe, South Africa and India.  This is the first drug in last 45 years to be approved for treatment of tuberculosis.  The drug kills TB bacterium by blocking energy production of bacteria by targeting the enzyme ATP syntheses of tuberculosis bacterium.  This drug is also belonging to new chemical class name  diarylquinolines. In 2016, Indian government conditionally approved usage of bedaquiline in Drug resistant TB patients under the national RNTPC program. In 2014, WHO put bedaquiline on its coveted list of "essential medicines".

Admission

Admission
Free and open to all. Entry is on a first come, first serve basis.